Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
04/2003
04/17/2003CA2460690A1 Method of treating hepatitis virus infection with a multiphasic interferon delivery profile
04/17/2003CA2460625A1 Structural and cytoskeleton-associated proteins
04/17/2003CA2460480A1 Molecules for disease detection and treatment
04/17/2003CA2460476A1 Protein modification and maintenance molecules
04/17/2003CA2460341A1 Methods of treating liver fibrosis and hepatitis c virus infection
04/17/2003CA2458645A1 Intracellular signaling molecules
04/17/2003CA2458392A1 Carbohydrate binding domain containing fusion proteins for delivery of therapeutic and other agents, and compositions containing them
04/16/2003EP1302542A1 Novel physiologically active peptide and use thereof
04/16/2003EP1302541A1 Receptor protein specifically recognizing bacterial dna
04/16/2003EP1302476A1 Reduced fk228 and use thereof
04/16/2003EP1302468A1 Processes and intermediates for manufacturing retroviral protease inhibiting compounds
04/16/2003EP1302207A2 Method for preparing an antihypertensive agent containing a dipeptide as active ingredient
04/16/2003EP1302206A1 Methods and means for the use of the adventitial toll-like receptor
04/16/2003EP1301797A2 Antimicrobial agent
04/16/2003EP1301624A2 Preprocalcitonin as tumor rejection antigen precursor and uses thereof
04/16/2003EP1301614A1 Codon-optimized papilloma virus sequences
04/16/2003EP1301611A2 Human rrp sequences and methods of use
04/16/2003EP1301606A1 Expression system
04/16/2003EP1301605A2 Nk cells activating receptors and their therapeutic and diagnostic uses
04/16/2003EP1301602A2 Fh-binding protein of streptococcus pneumoniae
04/16/2003EP1301598A2 Cell cycle proteins and mitosis-associated molecules
04/16/2003EP1301597A2 Methods and compositions relating to muscle selective calcineurin interacting protein (mcip)
04/16/2003EP1301595A2 G-protein coupled receptors
04/16/2003EP1301594A2 Non-endogenous, consstitutively activated known g protein-coupled receptors
04/16/2003EP1301593A2 ANTISENSE COMPOSITIONS TARGETED TO $g(b) 1? ADRENOCEPTOR-SPECIFIC MRNA AND METHODS OF USE
04/16/2003EP1301592A2 Recombinant bacterial phytases and uses thereof
04/16/2003EP1301535A2 G-protein coupled receptors
04/16/2003EP1301534A2 Mutated pf-4, its fragments and mutated fusion peptides, their analogues, corresponding dna, cdna and mrna sequences and their use for inhibiting angiogenesis
04/16/2003EP1301533A1 Tumour-associated antigen (b345), characterised by an amino acid sequence as in seq. id. no. 4
04/16/2003EP1301528A2 Peptides as ns3-serine protease inhibitors of hepatitis c virus
04/16/2003EP1301527A2 Peptides as ns3-serine protease inhibitors of hepatitis c virus
04/16/2003EP1301525A1 Transforming growth factor beta (tgf-beta) blocking agent-treated stem cell composition and method
04/16/2003EP1301524A1 B7-like polynucleotides, polypeptides, and antibodies
04/16/2003EP1301486A2 Imidazolidinones as ns3-serine protease inhibitors of hepatitis c virus
04/16/2003EP1301214A2 Methods of transducing neural cells using lentivirus vectors
04/16/2003EP1301213A2 Multi-component biological transport systems
04/16/2003EP1301211A2 Multifunctional nanodevice platform
04/16/2003EP1301206A1 Treatment of central nervous system diseases by antibodies against glatiramer acetate
04/16/2003EP1301202A2 Genetically-engineered mhc molecules
04/16/2003EP1301201A1 Treatment of glycogen storage disease type ii
04/16/2003EP1301200A2 Peptide pharmaceutical formulations
04/16/2003EP1301199A2 Methods for therapy of neurodegenerative disease of the brain
04/16/2003EP1301198A2 Fusion protein for inhibition of lipoprotein secretion
04/16/2003EP1301196A2 Stimulation of bone growth with thrombin peptide derivatives
04/16/2003EP1301195A2 Pharmaceutical use of fibulin-1
04/16/2003EP1301182A2 Use of matrix metalloprotease inhibitors for the treatment of cancer
04/16/2003EP1301181A2 Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds
04/16/2003EP1301146A2 Artificial vascular grafts, and methods of producing and using same
04/16/2003EP1220896A4 Novel human lipase proteins, nucleic acids encoding them, and uses of both of these
04/16/2003EP1200105A4 Modified factor viii
04/16/2003EP1181047B1 Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product
04/16/2003EP1103270B1 Treatment of autoimmune diseases in mammals
04/16/2003EP1054691B1 Anti-enzyme antibodies for the treatment of the skin
04/16/2003EP1041997B1 Use of citrulline peptides derived from filaggrin for treating autoimmune diseases
04/16/2003EP1025126B1 Purification of molecules
04/16/2003EP1009442B1 Improvements in or relating to regulation of t cell activation
04/16/2003EP0921810B1 Reduction of the severity of host vs. graft reaction by down-regulating hsp60 autoimmunity
04/16/2003EP0918455B1 Use of galanin to repair nerve damage
04/16/2003EP0873404B1 Angiotensin converting enzyme inhibitors
04/16/2003EP0824544B1 Peptidyl compounds which inhibit metalloproteinase and tnf liberation and their therapeutic use
04/16/2003EP0804481B1 Somatostatin derivatives and their radiolabelled products
04/16/2003EP0789591B1 Methods for identifying individuals suffering from a cellular abnormality
04/16/2003EP0773955B1 New thrombin inhibitors, their preparation and use
04/16/2003EP0769958B1 Inhibitors of leukocyte adhesion
04/16/2003EP0750508B1 RETROPEPTIDES, ANTIBODIES THERETO, AND USES THEREOF FOR VACCINATION AND $i(IN VITRO) DIAGNOSIS
04/16/2003EP0742796B1 Il-3 variant hematopoiesis fusion protein
04/16/2003EP0654083B1 Ptp-d subfamily of protein tyrosine phosphatases
04/16/2003EP0649414B1 Opioid diarylmethylpiperazines and piperidines
04/16/2003EP0642356B1 Antibodies to p-selectin and their uses
04/16/2003EP0605442B1 Recombinant antibodies for human therapy
04/16/2003EP0591462B1 Universal donor cells
04/16/2003CN1411552A Gas sensor
04/16/2003CN1411512A Chimeric immunogenic compositions and nucleir acids encoding them
04/16/2003CN1411508A Oligonucleotides modulating expression of enzymes involved in synthesis of melanic pigments
04/16/2003CN1411467A Compounds and use thereof to modify transport across cell membranes
04/16/2003CN1411386A Treatment of subnormal bone mineral density
04/16/2003CN1411376A Novel helicobacter pylori-binding substances and use thereof
04/16/2003CN1411369A Biodegradable microparticles with novel erythropoietin stimulating protein
04/16/2003CN1410538A Production and use of high expression, high purity, high activity gene recombinant human lysozyme
04/16/2003CN1410537A Production method of freeze dried human zymoplasm
04/16/2003CN1410536A Human source aprotinin gene, protein of said gene code and its application
04/16/2003CN1410448A Terminal blocked pentahelicoprotein and its use
04/16/2003CN1410447A Sequence number3 bioactive peptide
04/16/2003CN1410446A Sequence number4 bioactive peptide
04/16/2003CN1410445A Sequence number5 bioactive peptide
04/16/2003CN1410444A Sequence number9 bioactive peptide
04/16/2003CN1410443A Sequence number8 bioactive peptide
04/16/2003CN1410442A Sequence number1 bioactive peptide
04/16/2003CN1410441A Sequence number2 bioactive peptide
04/16/2003CN1410440A Sequence number6 bioactive peptide
04/16/2003CN1410439A Sequence number10 bioactive peptide
04/16/2003CN1410438A Sequence no.25 bioactive peptide
04/16/2003CN1410126A Recombinant human interferon alpha nose drops and its production technology
04/16/2003CN1410059A Treating method and medicine kit containing somatotrophic hormone secretory agent
04/16/2003CN1410054A II type collagen water soluble dispersion composition, its preparation method and application
04/16/2003CN1105728C Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
04/16/2003CN1105726C Human calcitonin analogue
04/16/2003CN1105725C Modulators for functions of FAS/APO1 receptors
04/16/2003CN1105577C Parathyroid hormone and raloxifene for increasing bone mass
04/16/2003CN1105576C Insulin analog formulation
1 ... 1866 1867 1868 1869 1870 1871 1872 1873 1874 1875 1876 1877 1878 1879 1880 1881 1882 1883 1884 1885 1886 ... 3163